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ABSTRACT
The medical application of injection of monoclonal antibodies using a controllable auto-loading
needle-free jet injector has been evaluated for two potentially limiting factors: viscosity of the
formulation and shearing of the antibody during ejection. We used the Hepatitis B monoclonal
antibody C86322M for its easy access and widespread usage. We used repeatability studies of
glycerol at up to 200 m/s and 200 ptL delivery volume to demonstrate precision at viscosities up
to 21.6x10~ Pa-s. We determined that viscosity alone would not limit the jet injector's
performance. Additionally, we evaluated the integrity of the antibody post-ejection using the
enzyme-linked immunosorbent assay (ELISA) and gel electrophoresis methods. Using the
ELISA method, we compared the ability of the antibody to bind to its specific antigen, HBsAg,
both before and after ejection at multiple speeds. Changes in molecular size and charge of the
monoclonal antibodies were evaluated by gel electrophoresis, more specifically with SDS
polyacrylamide gels in reducing and non-reducing situations, native gel electrophoresis, and IEF
gel electrophoresis. Most of these techniques revealed little to no change between pre-ejectate
and ejectate migration, indicative of an unchanging molecular size and overall charge. However,
with IEF gel electrophoresis, we observed two extra residues around a pI of 6.8. A change in
charge due to alterations of protein side-chains may affect the stability of the molecule, and so
this result is worth further pursuing on a quantitative basis. Despite this possibility, overall we
have demonstrated that at 1 g/L, no significant aggregation or degradation results from jet
ejection.
Thesis Supervisor: Ian Hunter
Title: Hatsopoulos Professor of Mechanical Engineering
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1. Introduction
1.1 Needle-free jet injector
The development of a controllable auto-loading needle-free jet injector using a Lorentz-
force motor and software-based control system has opened the doors for many possibilities in the
field of medicine. This platform technology, which uses a two phase injection profile consisting
of a brief high pressure pulse followed by a longer, lower pressure follow-through, allows for
robust and precise control over coil position and thereby over both the depth and volume of drug
delivered. In addition, the bi-directionality of the system potentially provides a more efficient
method of drug loading, re-loading, and reconstitution. Other benefits of the newly-prototyped
jet injector are the eradication of needles that may cause accidental needle stick injuries, cross-
contamination, the reduced person-time required for vaccination, and the potential to reduce both
drug volume and therefore number of injections leading to a conservation of resources.
1.2 Monoclonal antibodies
Monoclonal antibodies (MAbs) are a broad class of bio-therapeutics that can be used to
treat certain cancers and autoimmune diseases (Adams & Wiener, 2005; and van Vollenhoven,
2009). Because of their requisite high volume and high viscosity in order to be effective, these
antibodies are often difficult to deliver. Currently, many MAbs must be delivered intravenously.
While this presents as the fastest way to deliver medication throughout the body, delivery can be
slow, there is the risk of infection, phlebitis, infiltration, and embolism. Delivery to the
subcutaneous layer also carries a risk of infection and abscess at the site of injection. It is also
problematic for people with belenophobia and contributes to reduced compliance. Several
properties of the linear Lorentz-force actuated needle-free injector make it an attractive
alternative delivery system for this class of bio-therapeutic.
1.3 Jet injector application
It has already been demonstrated that needle-free jet injection is a significant
improvement over the traditional method of injection by needle and syringe for many reasons,
including infection prevention, safety, and ease of use. In addition, the needle-free jet injector
has potential applications in many different branches of medicine that previously utilized needles
for injection. Herein we evaluate the feasibility of using a jet injector to deliver Hepatitis B
monoclonal antibody (MAb). Hepatitis B MAb is one example of a broad class of bio-
therapeutic compounds (Lynch et al., 2009). With their development has come the need for more
innovative and controllable delivery devices able to deal with issues of high volume, high
viscosity, and variable drug state (e.g. lyophilized powder or particulate).
High viscosity due to formulation and/or MAb concentration could result in poor
repeatability due to increased variability in the volume and/or depth of drug delivered while very
high molecular weight protein or high viscosity has been shown, in specific cases, to cause high
shear stress and resultant denaturation (Jaspe & Hagen, 2006). As such, this project intends to
determine whether repeatability of delivery and/or shear-induced inactivation of Hepatitis B
MAb preclude its being delivered using our Lorentz-force actuated needle-free jet injector.
2. Background
2.1 Needle-free jet injector
A jet injector platform has been developed that offers improvements over previous jet
injectors through the use of a controllable linear Lorentz-force actuator and software-based
control system. All jet injectors require a method of temporarily storing energy before
transferring kinetic energy to a liquid drug. Currently, commercially available devices utilize
compressed springs, compressed gases, or explosive chemicals for energy storage, all of which
are relatively limited in terms of varying the jet velocity over the time-course of the injection.
The control of the volume and depth of delivery was thus a primary consideration in the
development of the new class of jet injectors outlined here.
2.1.1 Linear Lorentz-force actuation
This novel jet injector uses a linear Lorentz-force (voice coil) motor, which is an
electromagnetic actuator commonly used in audio speakers. When a voltage is supplied by a
linear amplifier (AE Techron LVC 5050), the effective current passes through a coil of copper
wire. This copper coil consists of six layers of copper wire tightly wound on an Acetal co-
polymer former, and provides an effective resistance of 11.3 Q. The current generated causes
changes in the magnetic field of an 8 mm portion of the copper coil, resulting in an axial force of
up to 200 N. This force is applied to the 3.16 mm diameter piston, which then pressurizes and
accelerates the fluid within the ampoule out through a small orifice 221 pm in diameter. These
ampoules (InjexTM Ampoule, part #100100), which are commercially available, accommodate a
volume of 300 pL over a 30 mm stroke length.
Using the three-position slide switch, the user can permit for manual loading of the
ampoule, locking of position, and a ready-to-inject mode. A switch on the back of the injector
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also allows for a slow retraction of the piston so that the ampoule can be easily reloaded under
servo control. A photograph of the handheld jet injector and a cutaway model of the Lorentz-
force motor can be seen in Figure 1 below.
ampoule magnet
ra piston b
Figure 1: (a) Handheld jet injector, and (b) Lorentz-force motor.
Taken from Taberner et al., 2010.
2.1.2 Software-based control system
The graphical user interface of the host application allows the operator to define and
preview a jet injection waveform using four inputs: the desired initial jet velocity (Vjet), the time
period for which Vjet is maintained (Tjet), a typically slower follow through velocity (Vft), and the
total injection volume. In adjusting the profile of applied voltage to the coil over time, we can
control the force and position of the piston during ejection. These jet injectors have the ability to
deliver injections using pre-defined pressure profiles (i.e. waveforms). The two phase injection
profile, an example of which is seen in Figure 2, consists of a brief high velocity pulse (Vjet)
required to penetrate the target tissue to a desired depth followed by a longer and lower-pressure
follow-through (Vft) that permits the bulk volume of drug to be delivered at this lower velocity.
This injection profile reduces the potential for shearing while permitting absorption into the
tissue. A linear slide potentiometer (750 V/m) measures the position of the coil. With this
measurement of the coil position and knowledge of the cross-sectional area of the piston (1 x 10-7
m3), the swept volume throughout the time course of the ejection can be computed. This
injection profile allows for more control over the depth at which an injection needs to be
delivered and the volume of delivery.
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Figure 2: Injection waveform for delivering 150 IL of water at 200 m/s.
The software-based system takes advantage of the bi-directionality of the system by using
its auto-reloading feature to increase efficiency during several successive ejections. This feature
uses full real-time feedback control, drawing the piston back in small steps and using the position
sensor as a reference. The drive power is modulated by the computer over the entire reloading,
and the non-uniform friction is accounted for over the travel of the piston. The auto-reloading
feature thus allows for relatively constant-velocity reloading, something difficult to do during
manual reloading due to human capabilities and the nature of some of the more viscous
compounds.
2.1.3 Competitive advantages of jet injector
The jet injector offers many improvements over the conventional needle and syringe.
Even when handled by trained professionals, rate of delivery by hypodermic needles will vary.
Automation by the control system of the jet injector allows for consistent speed and time of
delivery. Jet injection alleviates the two primary concerns associated with this current method of
drug delivery by eliminating both needle stick injuries and the high cost associated with the need
for sharps disposal. Additionally, the ampoule contains a smaller orifice of 200 pm in diameter
compared with a typical 28 gauge needle with outer diameter of 362 pm. The decreased puncture
size reduces recovery time and the potential for infection. Finally, the use of the jet injector
increases acceptance and patient compliance, decreasing instances where a user or caregiver
might deviate from a strict dosing regimen due to belonephobia (Hogan, 2011).
The software-based control system also has improved repeatability over previous jet
injectors because of its ability to use a two-phase pressure profile during the entire time-course
of delivery. The controllability of our jet injector becomes essential for two main reasons. First,
it is able to regulate the depth and dose of the drug delivered, ensuring penetration of skin and
then preventing excessive fluid from splattering. This control of the velocity allows for more
efficient delivery of drug, reducing the potential for shearing while enabling absorption within
tissue. This efficiency decreases the volume required for effective delivery, which also decreases
the time of injection. Second, the four user-determined parameters (Vjet, Tjet, Vft, and volume)
allow for flexibility in injection depth and drug volume. The injection profile can thus be
adjusted for a wide range of skin types and a wide range of medical applications.
Hemond et al., 2006, has shown that the controllable jet injector is capable of delivering a
specific volume of fluid to a specific depth based entirely on the four input parameters
mentioned previously. Under auto-loading computer control, the ejected volumes match to
within 3 percent tolerances, indicating high accuracy of the software system. Furthermore,
Taberner et al., 2010, has demonstrated the ability to both accurately and precisely control
delivery of up to 250 pL volume into acrylamide gels (for its analogous properties with living
tissue) and post-mortem animal tissue. Despite variations in skin type due to stiffness and
thickness, the jet injector can effectively and repeatably breach the skin and then deliver fluid
volume to a pre-determined depth. The success of these experiments indicates that the
controllable Lorentz-force actuated jet injector can be an attractive alternative drug delivery
system.
2.2 Monoclonal antibodies
Monoclonal antibodies are characterized by their specificity to a given antigen. They are
used extensively within the fields of biology and chemistry, and have some applications in the
medical field as far as both diagnostic tests and therapeutic treatments. The structure of an
antibody (Figure 3) contains heavy and light chains held together by a combination of non-
covalent interactions and covalent disulfide bonds. The Y-shaped structure is bilaterally
symmetric, and the two antigen-binding sites are located at the tips of the "Y" (Pierce).
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Figure 3: Inmunoglobulin (antibody) structure.
Taken from Pierce.
Monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to
target molecules within a patient's body. Unlike vaccines, in which a small amount of antigen is
designed to elicit an immune response, monoclonal antibodies are intended to target specific
molecules within the pathway of a disease, bind to these targets thereby disrupting the disease
pathway. While monoclonal antibodies have shown potential in a clinical environment,
ultimately monoclonal antibodies are only produced when necessary because their production is
time consuming and expensive. Even so, their unique specificity has instigated investigation of
their usage in several previously untreatable diseases. Over twenty monoclonal antibodies,
including unmodified antibodies and antibodies armed with toxins or radionuclides, have been
approved to prevent allograft rejection or to treat autoimmune diseases and cancer. Hundreds of
monoclonal antibodies are also in clinical studies (Waldmann, 2003).
Murine antibodies have a short half-life in vivo and only limited penetration into tumor
sites (Stem & Hermann, 2005). Murine antibodies have been generally replaced by humanized
and chimeric antibodies in modem therapeutic antibody applications (Nelson et al., 2000). The
intention of these two types of antibodies is to achieve a more "human-like" antibody, so that
immunogenicity might be reduced while a specific immunologic effect is simultaneously
increased (Riechmann et al., 1988).
2.3 Hepatitis B monoclonal antibody
Our initial objective was to evaluate delivery of a monoclonal antibody with indication
for the treatment of rheumatoid arthritis, a disease afflicting 1.5 million adults in the United
States (Myasoedova et al., 2010). This was later revised to assessment of the ability of the jet
injector to deliver chemokine receptor type 5 (CXCR5) monoclonal antibody. Anti-CXCR5
antibody binds to CXCR5 (Allen et al., 2007; and Zlotnik et al., 2006), a G-protein coupled
receptor, and is of potential use in the treatment or prevention of CXCR5 related diseases or
disorders such as rheumatoid arthritis (Lee et al., 2011) and in the migration of B cells into
lymphoid microenvironments (Cyster, 1999). Timely availability of CXCR5 could not be
guaranteed and as such the monoclonal antibody chosen for this study was a murine antibody
against Hepatitis B surface antigen (HBsAg).
Hepatitis B is an infectious illness caused by the Hepatitis B virus (HBV). It has inflicted
2 billion people, about one third of the world's population (Hepatitis B Foundation, 2009).
Approximately 90 percent of healthy adults who are infected will recover and develop protective
antibodies against future Hepatitis B infections. However, about 5 percent will be unable to
recover completely and will develop chronic infections. For this reason, the World Health
Organization recommends prevention using the Hepatitis B vaccine, which has a 95 percent
success rate (WHO, 2006).
HBsAg, a viral envelope protein and major component of the Hepatitis B vaccine, is
produced by yeast cells into which the HBsAg sequence has been inserted (Miyanohara et al.,
1983). The Hepatitis B vaccine, like all vaccines, works by injecting antigen into the body and
inducing an immunogenic response (creation of antibodies). The presence of HBsAg in human
sera indicates current Hepatitis B infection, and people who develop antibodies against HBsAg
are usually considered non-infectious.
We chose to use this particular antibody for several reasons. For HBsAg and its
monoclonal antibody, antigen/antibody recognition is structural and not sequence based. As we
will illustrate in Section 2.5, one of our primary goals is to evaluate whether monoclonal
antibody will shear during ejection. With antibody/antigen structural recognition, we can use the
antigen HBsAg to evaluate antibody binding effectiveness after ejection. A reduction in
effectiveness might indicate significant shearing. This antibody was also chosen for its
availability. As it is used as a Hepatitis B diagnostic to determine the presence of HBsAg, it is a
relatively common antibody. While antibodies are not typically used as vaccines, prophylactic
use of human monoclonal antibodies to HBV has been shown to reduce viral load in individuals
exposed to the virus (Dagan et al., 2003). In summary, monoclonal antibody to HBsAg is an
appealing choice of antibody due to its structural recognition of HBsAg, potential clinical use,
and ready availability.
2.4 Applications of jet injection
While intravenous (IV) injection is the current gold standard for delivery of monoclonal
antibody and other voluminous, highly viscous formulations, IV therapy does have several key
issues as mentioned in the Introduction (Bohony, 1993). These include but are not limited to
infusion phlebitis (inflammation of the vein), infection, bruising, extravasation, and infiltration.
By reducing the size of the puncture in the body, the needle-free jet injector can reduce the
chances of opportunistic infection as well as the potential for contamination of the formulation.
With further evaluation of the injection process in a clinical setting, the jet injector technology
might be able to simplify a physician's task of safely and efficiently transferring a large quantity
of drug into a patient's body.
2.5 Major concerns
One major concern for this application of the jet injector is the viscosity of antibody
formulations on the order of 10 g/L to 200 g/L (Marques et al., 2009). Previously, the jet injector
had not been tested with highly viscous compounds. It is possible that the force required at
viscosities comparable to that of monoclonal antibody concentrates exceeds the voltage
limitations of the jet injection system. In addition, viscous compounds are characterized by their
resistance to change in inertia. At the end of an ejection of highly viscous fluid, it is possible that
this quality of the fluid will cause it to resist deceleration and continue to exit the orifice. In this
instance, the ability of the jet injector to deliver monoclonal antibodies would be impeded by the
lack of accuracy and/or precision in each ejection.
The second major concern for this application is the integrity of monoclonal antibody
concentrates after ejection. At injection speeds required to pierce the epidermis, the flows within
the ampoule and through the exiting orifice are turbulent. This results in a velocity profile as in
Figure 4, where the no-slip condition at the walls of the ampoule cause a high shear force at
those locations. Equation 1 shows the shear stress on the antibody (TAb) when the antibody is
located near the walls. It is a function of the viscosity of the fluid (p) and slope of the fluid
velocity ( ), in addition to the radius (R) of the monoclonal antibody.dy
dv
TAb = dy Iy=R (1)
Velocity
Shear forces at walls D
y
Figure 4: Velocity profile of fluid within ampoule.
At the orifice, there is an even higher shear force due to the fluid being pressurized and
directed from the larger cross-sectional area ampoule to the smaller cross-sectional area of the
orifice. Because of the large size of individual monoclonal antibodies and these high forces, it is
likely that at some threshold concentration and ejection speed the antibody will be sheared. Our
goal is to determine whether concentrations required for effective delivery in a medical setting
would cross this threshold and limit the possibility of using the jet injector in this application.
3. Experimental Methods
3.1 Pre-calibration
The current jet injector requires an initial calibration, which defines a relationship
between input voltage and the steady state jet velocity. While there are several analytical
methods that relate pressure imposed on the fluid with the resulting jet speed, in this case the use
of the disposable InjexTM piston makes static and sliding friction at the piston-ampoule interface
a significant component of the overall load imposed upon the Lorentz-force motor (Tabemer et
al., 2010). The relationship between input voltage and jet velocity can be attained by conducting
a series of increasing voltage step-response experiments. In each experiment, the steady-state
coil current can be measured and the steady state force calculated. Steady state speed is
necessary in order to ensure that applied force is balanced exactly by the friction of the piston-
ampoule interface and fluid impedance created by the orifice. At steady state, inertia is
negligible. The relationship between input voltage and steady state is best approximated with a
polynomial fit.
Figure 5 shows the results of our calibration for three different coils. Coils 1 and 2 had a
resistance of 11.3 Q, and Coil 3 was a shorter coil with a resistance of 9.3 Q. These three coils
were used during the repeatability experiments. While they show slightly different velocity-
voltage relationships, they are similar in terms of accuracy and precision during delivery of pre-
set volumes.
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Figure 5: Water calibrations ofjet injector using different copper coils.
After calibrating, the user must input four parameters: the initial jet velocity (Vjet), the
time at the initial jet velocity (Tiet), the follow-through velocity (Vfa), and the desired volume of
fluid to be delivered. These factors determine the depth of injection along with the volume and
time taken during each sample, and are then used to define the injection profile of customized
waveforms.
Each ampoule holds 300 ptL of fluid and each piston has 30 mm of travel. To ensure that
the piston never runs up against the ampoule, we never inject more than 250 pL before
reloading. The voltage, current, velocity, and displacement (as determined by monitoring the
piston of the voice coil using a 10 kW linear potentiometer with a bandwidth exceeding 1 kHz),
and time are monitored in real time using the control software. These values are graphically
presented along with the calculated delivery volume. A sample waveform for a water ejection
can be seen in Figure 6.
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Figure 6: Coil position, current, and voltage during ejection of 150 pL of water at 200 m/s.
3.2 Ejection studies to evaluate repeatability of delivery volumes
3.2.1 Repeatability of increasing concentrations of glycerol
Our intention was to characterize the ability of the jet injector to handle highly viscous
compounds, simulating the behavior of concentrated monoclonal antibody. To do this, we
decided to find a glycerol concentration that would have similar viscosity to that of such a
monoclonal antibody formulation, on the order of 1x1O-3 to 10Ox10-3 Pa-s. Pure glycerol, in
comparison, is about 1.2 Pa*s (Lide, 1994). We characterized the behavior of the jet injector by
conducting repeatability studies, in which we repeatedly ejected fluid at constant volumes and jet
velocities. We assessed this behavior by evaluating the accuracy and precision of delivered fluid
volumes.
To investigate whether or not high-viscosity fluids would limit the jet injector's ability to
deliver accurate volumes, we chose to use glycerol for its high viscosity and solubility in water.
We first used solutions of glycerol in increasing concentrations to establish a concentration that
could be repeatably delivered by the current jet injector. In order to do this, we chose to restrict
the delivery parameters to a Vjet of 100 m/s, Tjet of 10 ms, Vft of 50 m/s, and volume of 100 pL.
This limit was determined based on when the voltage supplied by the amplifier reached close to
300 V, the limit of the amplifier. At such high voltages, we would expect to experience a high
shear force at the piston-ampoule interface accompanied by minimal travel of the piston itself.
We used 0, 1, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 percent concentrations of glycerol in
distilled water for this task. A sample size of ten was used for each respective concentration, in
order to establish the precision of the system.
We then selected concentrations of glycerol with a similar viscosity to either the buffer or
antibody-buffer formulation and proceeded to do repeatability studies. The viscosities we used
were 0, 1, and 10 percent for similarity to buffer, and 30, 50, and 70 percent concentrations for
similarity to the monoclonal antibody-buffer formulation. In these repeatability studies, the
desired Vjet and volume were varied such that at a given Vjet, the repeatability of ejected volumes
was quantified by delivery of 50, 100, 150, and 200 ptL of a known concentration of glycerol,
each into a set of pre-weighed vials containing cotton wool. The samples were injected into 1.5
mL Eppendorf tubes containing a small quantity of cotton to encourage absorption and prevent
splattering. The difference in weights pre- and post-ejection would reveal the ejected mass.
Using the density at that volume, we could calculate injection volume and compare it to the pre-
set volume.
The procedure for measuring viscosity is delineated in Section 3.3. These sets of data,
one relating glycerol percentage to repeatability and the other relating viscosity to glycerol
percentage, allow us to roughly extrapolate the behavior of monoclonal antibody concentrations
at similar viscosities. This estimate serves to make an initial review of the possibility of using a
jet injector to eject monoclonal antibodies.
3.2.2 Repeatability of MAb buffer formulation
The composition of the buffer we used was 25 mM histidine, 50 mM arginine, 5 percent
sucrose, and 0.2 percent polysorbate 20. This polysorbate buffer formulation was used for the
stabilization effects of the polysorbate, which have been shown during shaking stress
experiments of a polysorbate-antibody solution. A polysorbate 20 level of 0.005 percent was
found sufficient to stabilize both at low and high antibody concentration against antibody
aggregation and precipitation (Mahler et al., 2009). Viscosity data supplied by colleagues using a
comparable buffer solution indicated that formulations of this buffer with monoclonal antibody
could have temperature-dependent viscosities ranging from approximately 2.6x 10-3 to 69.4x 10-3
Paes for a 5' to 25'C temperature range.
The viscosities of the polysorbate buffer at 50C and 25 0C fit into the range of viscosities
measured during the viscosity characterizations of different glycerol concentrations. Using the
same repeatability test as was used on the varying glycerol concentrations, we can then compare
the repeatability of the buffer to the repeatability of a similar glycerol solution. This provides an
estimate as to the ability of the jet injector to handle the polysorbate buffer, we can determine if
the composition of the buffer itself might be a deterrent in the performance of our jet injection
system.
3.2.3 Repeatability of buffer formulation containing MAb
In a clinical situation, a dose of monoclonal antibody could potentially be 200 mg and at
a much higher concentration of 175 g/L. We were unable to acquire such high concentration
Hepatitis B antibody. In order to get an initial estimate of the repeatability of delivery using a
monoclonal antibody, we used a 1 g/L solution of Hepatitis B MAb, diluted in polysorbate
buffer. Using the jet injector, we ejected replicates of 50 pL at 50, 100, 150, and 200 m/s in order
to evaluate repeatability of ejected volume.
3.3 Viscosity Measurements
The viscosities of these several of these formulations were measured and recorded using
a shear rheometer (TA Instruments AR-G2), so that we could relate our measured viscosities for
glycerol concentrations and buffer formulation with known values for buffer formulation
containing MAb. The viscosity of the buffer formulation containing MAb was not measured
using this method, primarily due to the cost of antibody and large quantity of solution required.
Our colleagues have indicated that an 87 g/L solution of MAb in buffer would have a viscosity
of approximately 2.6x 10-3 Pa-s. As we are using 1 g/L concentrations of MAb, we are working
with a solution with viscosity on the order of water (1.0x10-3 Pa-s).
We utilized a steady-shear experiment using a cone and plate method (Figure 7).
Approximately 2 mL of fluid was placed on the flat plate. A shallow cone (about 1 degree) above
the flat plate was entered into direct contact with the fluid, and the plate was spun. The forces on
the shallow cone were measured as a function of shear rate, which was varied from 0.1 to 100 s1
during a 10 second sample period. As glycerol is a Newtonian fluid, the identified viscosity for
each glycerol concentration was a ratio of resultant shear stress to the preset shear rate of the
fluid.
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Figure 7: Cone and plate rheometer.
Taken from Pressure Profile Systems.
3.4 Evaluation of MAb Integrity Following Ejection
To avoid loss due to backsplash, MAb was ejected into tubes containing cotton wool as
was done for volume repeatability studies with some modifications. Because post ejection
evaluation of MAb integrity required recovery of the ejected samples, the volume and packing of
the wool into tubes was adjusted by trial and error using ejection of water until a density was
achieved that prevented any sample from pooling in the bottom of the tube but also precluded
backsplash. Rather than using 1.5 mL Eppendorf tubes, 0.5 mL tubes were used as these could
then be seated in 2.0 mL tubes for sample recovery. In each case, sample was ejected into the
0.5 mL tube, the end of the tube clipped, the tube seated in a 2.0 mL tube, and the 2.0 mL tube
centrifuged at 13,000 rpm for 30 seconds. Volume recovered was determined by accessing the
difference in weight between the combination of tubes and cotton wool prior to and after
ejection. On average (N =8), ejection of 50 iL of water resulted in recovery of 34 ± 2 iL or 71%
of the ejectate. A schematic of the procedure is shown in Figure 8. This procedure was then
implemented for recovery of ejected MAb. Recovered samples were stored at 4'C until ready for
evaluation.
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Ejected ELISA plate
MAb
Figure 8: Procedure to evaluate the integrity of monoclonal antibody after ejection.
3.4.1 MAb integrity as determined by ELISA
The ELISA (enzyme-linked immunosorbent assay) is a very versatile, highly sensitive,
quantitative technique the permits detection of specific antibodies, soluble antigens, or cell-
surface antigens. All ELISAs require that a solid-phase reagent (antigen or antibody) interact
with a secondary or tertiary reagent (antigen or antibody) either of which is covalently coupled to
an enzyme. Unbound reagents are removed by washing and unbound sites blocked using a range
of proteins from non-fat milk to purified proteins to reduce non-specific binding of proteins. A
substrate (chromogenic or fluorogenic) is then added which is hydrolyzed by the bound enzyme
resulting in a colored or fluorescent product. The relative amount of this product is proportional
to the amount of antigen or antibody being analyzed (Abmayr et al., 1999). In our case, we
wanted to evaluate the ability of the ejectate, a Hepatitis B MAb (C86332 MAb from Meridian
Life Science, Inc.), to bind with the 24 kDa recombinant HBsAg (R86783 from Meridian Life
Sciences, Inc.).
Prior to evaluation of ejectates using the ELISA, we needed to determine the optimal
concentration of antigen and antibody required to generate the best signal to noise ratio, provide
a robust and reproducible assay, and provide a measure of the antigen over a biologically
relevant range (dynamic range) (Pierce). A criss-cross ELISA with different antigen and primary
antibody concentrations was conducted initially in order to determine optimal signal for both
primary antibody and antigen. Optimal signal was defined as a high signal below saturation and
without loss of sensitivity. The antigen concentrations we used were 5000, 2500, 1250, 625,
312.5, 156.3, 78.13, 39.06, 19.53, 9.77, 4.88, and 0 pg/L. The monoclonal antibody
concentrations used were 3550, 1775, 887.5, 443.75, 221.88, 110.94, 55.47, and 27.73 [tg/L.
The criss-cross ELISA used allowed us to define an optimal HBsAg (initial antigen)
concentration and an optimal C86322M (primary antibody) concentration. As seen in Figure 9,
the antigen concentration we chose was 300 pg/L and the monoclonal antibody concentration we
chose was 150 pig/L. The box shows comparable antigen-antibody concentrations to the one we
chose. The absorbance for this point was thus approximately 1, which is just below saturation.
This point was chosen to be just below saturation, to emphasize maximum sensitivity if any of
the concentrates were demonstrating a lower absorbance after ejection. Our primary objective
was to ensure that if the monoclonal antibody had been sheared that we might be able detect this
from the inability of the secondary antibody to effectively bind.
Figure 9: Results from criss-cross ELISA.
With the results optimized from this ELISA, we proceeded to do another ELISA that
would compare ejected monoclonal antibody formulation with pre-ejected monoclonal antibody
formulation. We set up a plate using the optimized antigen and antibody concentrations from
above along with our ejectates and pre-ejectate in triplicate. The jet injector speeds used to
potentially shear our antibody were 50, 100, 150, and 200 m/s. In addition, we included controls
of no antigen with our Ab formulations, a non-specific antigen (Collagen-III Ag) with our Ab
formulations, and HBsAg with the Collagen-III Ab6310. Each of our controls was intended to
yield no binding. Resulting differences in absorbance of the ejectates and pre-ejectate detected
using the photo-spectrometer would indicate shearing of the monoclonal antibody.
3.4.2 MAb integrity as determined by gel electrophoresis
3.4.2.1 SDS polyacrylamide gel electrophoresis
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), is a technique
widely used to separate proteins according to their electrophoretic mobility. This mobility can be
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a function of polypeptide chain length or molecular weight. In SDS-PAGE, samples are mixed
with SDS, an anionic detergent that denatures secondary protein structure and tertiary structure
with the exception of disulfide bonds. The latter are broken by addition of p-mercaptoethanol.
Together with SDS and the p-mercaptoethanol, the sample is heated to approximately 95'C
allowing the SDS to bind to most proteins in a constant weight ratio. Given the charge due to the
bound SDS dominates the intrinsic charge on the protein, the resulting SDS-protein complexes
have identical charge densities and as such migrate in the gel based on size (Hames, 1981). This
procedure permits both size and composition of the sample to be determined.
Reducing SDS-PAGE was used to evaluate Hepatitis B MAb structure before and after
ejection at variable velocity using the needle-free jet injector. More specifically, given that we
are using a purified MAb, we were attempting to determine if ejection resulted in degradation.
This degradation might be inferred by accumulation of products other than the expected MAb
subunits. A constant concentration of each sample mixed with two volumes of Laemmli sample
buffer (62.5 mM Tris-HCl, pH 6.8, 25% glycerol, 2% SDS, 0.0 1% bromophenol blue) containing
5% p-mercaptoethanol was loaded into the appropriate wells of a 4 to 20 percent gradient
polyacrylamide gel. Gels were subjected to electrophoresis for 40 minutes at 150 V, after which
they were washed three times with distilled water (5 minutes/wash), stained with Coomassie
Brilliant Blue R-250 for 60 minutes, de-stained in water for 30 minutes, and photographed using
a Canon EOS-IDs camera. A schematic of the gel setup for SDS-PAGE is shown in Figure 10.
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Figure 10: Setup for SDS-PAGE gel cassettes.
When voltage is applied, the negatively charged molecules migrate through the gel to the positively charged anode.
Schematic taken from Wagner, 2011.
At least one well of each gel was loaded with KaleidoscopeTM pre-stained standards made
up in Laemmli buffer containing 5% p-mercaptoethanol and heated to 95'C for 5 minutes prior
to loading. These KaleidoscopeTM samples contain proteins with known molecular weights,
ranging from 5,886 Daltons for aprotinin to 192,988 Daltons for myosin, and allow us to
estimate the molecular weight of each component of our antibody concentrates following
electrophoresis.
Hepatitis B MAb samples were also subjected to SDS-PAGE under non-reducing
conditions. The difference between reducing and non-reducing SDS-PAGE concerns the
treatment of the samples prior to loading; the procedure for gel electrophoresis is the same for
reducing SDS-PAGE. In non-reducing SDS-PAGE, sample is mixed with Laemmli buffer that
does not contain p-mercaptoethanol and the samples are not boiled prior to their being loaded
onto the gel. However, the presence of SDS denatures the protein giving it a net negative charge
and constant charge-to-mass ratio.
3.2.2.2 Native gel electrophoresis
The difference between SDS-PAGE and native or non-denaturing polyacrylamide gel
electrophoresis involves differences in both sample preparation and running conditions. Samples
for native gel electrophoresis are diluted in buffer lacking both SDS and p-mercaptoethanol and
are not boiled prior to loading. In addition, SDS is not included in the electrophoresis buffer. The
net result is that samples are separated on the basis of both charge and size (i.e. hydrodynamic
size) with preservation of subunit interactions, native protein conformations, and activity.
Changes in stability resulting in degradation or aggregation for example will alter the charge or
conformation of the test molecule and manifest as a change in migration on the gel compared to
an intact sample molecule.
3.4.2.3 IEF gel electrophoresis
IEF (isoelectric focusing) gel electrophoresis uses ampholytes (i.e. molecules with both
positively- and negatively-charged moieties) to establish a pH gradient. Under an electric field,
proteins will migrate through the gel until they reach their isoelectric point (pI) or the point at
which they have no net charge. If the charge on the protein changes as in degradative processes
such as deamidation, this change should be reflected as a change in the pI.
4. Results and Discussion
4.1 Ejection studies to evaluate the repeatability of delivery volumes
4.1.1 Repeatability of increasing concentrations of glycerol
These solutions were ejected from the jet injector at 100 m/s for a volume of 100 pL
(shown in Figure 11). Additionally, the limit of ejection for this experiment occurred at 80
percent glycerol. We were unable to eject the 90 percent or 100 percent solution without risking
excessive current and possibly short-circuiting the system.
From these data, we know that the jet injector's limiting viscosity occurs between that of
80 and 90 percent, or between 49.7x10-3 and 169.7x10-3 Pa-s. We calculated injection volumes
by taking the difference between post-ejection vials containing fluid and dry pre-weighed vials.
This procedure is detailed in Section 3.2.1. After ejecting using the jet injector and calculating
injection volumes using this method, we found that ejection volumes were constant as the
glycerol concentration (and viscosity) increased. The instrument's precision was fairly constant
with increasing glycerol concentration. On average, the jet injector was able to deliver 100.3
2.6 pL.
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Figure 11: Injection volumes with increasing glycerol percentage.
We also chose to investigate the repeatability of delivery for higher viscosities at
different delivery volumes and speeds. Figure 12a-f show repeatability of delivery for 0, 1, 10,
30, 50, and 70 percent solutions. As shown in the figure, the spread at each delivery volume and
jet injection speed increases as the glycerol concentration increases. However, even at 50 percent
glycerol with a viscosity of 6.6x10-3 Pa-s, the average error is 2.9 pL, compared to 2.0 pL for
pure distilled water.
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Figure 12a-f: Repeatability of delivery for 0, 1, 10, 30, 50, and 70 percent glycerol solutions.
Error bars show standard deviations above and below the mean.
While the repeatability studies for glycerol show a high degree of precision even at high
viscosities (70 percent glycerol), there are several notes to be made about the process. At higher
viscosities (above 6.6x 103 Pa-s corresponding to a glycerol concentration of 50 percent), there is
a tendency for the ampoule to collect air bubbles near the piston during reloading. Slow manual
reloading was required to minimize the presence of these pockets of air. Since the set velocity of
auto-reloading was comparably high, it could not be used. However, with the adjustment of a
slower auto-loading velocity, reloading of the piston becomes both more efficient and more
accurate.
Another note to make about the jet injection process is the effect of the quality of
ampoules on the behavior of the jet injector. The InjexTM Ampoule is a disposable and
commercially-available drug ampoule specifically chosen for its availability and relatively low
cost. Although this ampoule had been designed for single-use, we had been routinely achieving
50-100 injection cycles before the ampoule or piston exhibited evident wear and required
replacement (Taberner et al., 2010). With higher speeds and higher viscosities, this life cycle is
considerably shorter, sometimes even noticeably affecting accurate delivery in the first several
ejections. Rapid and successive ejections at 200 m/s are limited by the useful lifetime of the
ampoule. Since the ampoule is currently disposable, it may be beneficial to look into designing
and manufacturing ampoules made of more robust materials which could be intended for re-use.
4.1.2 Repeatability of MAb buffer formulation
Repeatability studies for the MAb buffer at both 5 and 25'C (Figure 13) showed a
comparable response with water. Initial jet velocities vary from 50 to 200 m/s. Standard
deviations, shown by error bars, are comparable to water and low-concentration glycerol. There
was not a significant difference in the behavior of the buffer at 5oC and the buffer at 25'C, which
could be expected due to the low viscosity (similar to water) in both instances.
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Figure 13: Repeatability of 100 pL MAb buffer ejections.
Error bars, while negligible, show standard deviations above and below the mean.
While the behavior of the MAb buffer during ejection was both accurate and precise, the
polysorbate within the buffer itself is an emulsifier, with some characteristics similar to soap.
When reloaded or ejected at high velocity, the buffer had a tendency to develop small bubbles in
the form of foam. With a slower reloading speed and diligent cleaning of the edges of the orifice,
this problem can be resolved. This phenomenon of the MAb buffer required careful monitoring
during auto-reloading and may have contributed to a small amount of error in the repeatability
studies. However, the benefits of the presence of polysorbate in the formulation outweigh the
error contributions. As remarked upon in Section 3.2.2, inclusion of polysorbate in the buffer has
been shown to stabilize the antibody from aggregation and precipitation.
4.1.3 Repeatability of buffer formulation containing MAb
Repeatability studies of monoclonal antibody in buffer showed that the jet injector
remained fairly accurate when delivering volumes of 50 gL. At higher speeds and particularly at
200 m/s, there is some inaccuracy in this method of measurement due to splash-back, despite the
presence of the cotton. As in the repeatability studies for the buffer alone, the tendency for the
polysorbate buffer to form froth may have also contributed to some error.
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Figure 14: Repeatability of Hepatitis B MAb delivery.
4.2 Viscosity measurements
4.2.1 Viscosity of increasing concentrations of glycerol
Using the rheometer, we developed relationships between the shear rate and shear stress
of glycerol at different glycerol concentrations, and were able to compare these viscosities with
those of our buffer formulation containing MAb. The results are shown in Figure 6. For our
glycerol concentrations, viscosities range from 1.73x10-3 Pa-s for a 1 percent solution up to
763x10~3 Pa-s for pure glycerol. This appears to be slightly low compared to tabulated values,
which show a viscosity of 1.2 Pa-s for pure glycerol as mentioned previously in Section 3.2.1.
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Figure 15: (a) Viscosities at increasing glycerol concentrations and shear rates.
(b) Viscosities as a function of concentration.
4.2.2 Viscosity of buffer formulation at variable temperature
The rheometer was used to find a viscosity for the buffer alone (25 mM L-histidine, 50
mM L-arginine, 5% sucrose, and 0.2% polysorbate 20), at two different temperatures, 50C and
25'C (Figure 16). These viscosities were 1.44x10-3 Pa-s and 0.93x10-3 Pa-s, respectively. These
viscosities for the buffer show that the presence of monoclonal antibody contributes significantly
to the viscosity of the final solution. This antibody-buffer solution is approximately 69.4x 10-
Pa-s for 25'C and 14.4x10 3 Pa-s for 5'C, as stated previously. When these viscosities are
compared to the viscosities for each of the glycerol concentrations, the polysorbate buffer falls in
between 0 and 1 percent glycerol solutions, while the antibody-buffer solution falls between a 60
and 70 percent glycerol solution.
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Figure 16: Viscosity of buffer formulation for MAb.
4.3 Evaluation of MAb integrity following ejection
4.3.1 MAb integrity as determined by ELISA
The ELISA was run to compare each of these ejectates with the untouched antibody (pre-
ejectate). As shown in Figure 12, there was not a statistically significant difference between any
of the ejectates and the pre-ejectate. As the Hepatitis B antigen-antibody relationship is a
conformational one (Section 2.3), this would seem to indicate that shearing during ejection was
negligible. If the antibody had been sheared, its ability to bind to antigen had not been noticeably
compromised and the method of ELISA thus could not definitively indicate shearing.
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Figure 17: Comparison of MAb after 50, 100, 150, and 200 m/s ejection with pre-ejectate.
Error bars show standard deviations above and below the mean.
4.3.2 MAb integrity as determined by gel electrophoresis
Several methods of gel electrophoresis were used to evaluate the integrity of the MAb
following ejection using the needle-free jet injector, each designed to tell us something about the
gross structure of the molecule.
4.3.2.1 SDS polyacrylamide gel electrophoresis
Initially, a constant amount (i.e. 5 pg) of each ejected sample was reduced and loaded
into individual wells for separation by SDS-PAGE. SDS-PAGE is often used to determine the
purity and/or heterogeneity of MAb's. Reduction of the disulphide linkages of IgG molecules
should yield two distinct bands corresponding to the heavy (~50 to 53 kDa) and light (~23 to
25 kDa) chains comprising the MAb (Pierce). The presence of additional bands could reflect
structural heterogeneity due to contamination with host immunoglobulins since MAb is derived
from ascites, differences in glycosylation prior to purification, or proteolysis prior to or after
purification (Grebenau et al., 1991); possibly due to handling and/or ejection. Reduction and
electrophoresis of the Hepatitis B MAb following ejection at variable velocity using the needle-
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free jet injection yielded two bands with relative molecular weights of approximately 53 and
25 kDa as expected for heavy and light chains comprising IgG molecules (Figure 18). A
comparable set of bands was observed in the pre-ejectate control sample.
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Figure 18: (a) SDS-PAGE of Hepatitis B MAb under reducing conditions. One part MAb (constant concentration of
5 pg assuming 1 g/L sample) was mixed with 2 parts Laemmli buffer (62.5 mM Trish-HCI, pH 6.8, 25% glycerol,
2% SDS, 0.01% bromophenol blue) containing 5% p-mercaptoethanol, heated to 95'C for 5 min, and loaded into
appropriate wells of a 4-20% polyacrylamide gel. Relative molecular weights of calibration proteins are indicated on
the right. Pre-ejectate served as a control. (b) Plot of relationship between logio molecular weight of known
calibration proteins and polyacrylamide concentration (%T). Relative molecular weights of unknowns, marked by *,
are determined by interpolation. Line of best fit is described by the equation, where x represents %T and y
represents the logio relative molecular weight.
Replicates of the samples separated by SDS-PAGE under reducing conditions were
evaluated under non-reducing conditions (i.e. no p-mercaptoethanol and no heating to 95*C). In
each case, 5 iL (5 pLg) of sample was mixed with 10 iL of Laemmli buffer minus s-
mercaptoethanol and samples loaded directly into the wells of a 4 to 20 percent polyacrylamide
gradient gel. Electrophoresis was as for reducing SDS-PAGE. Figure 19 shows that a major band
with mobility comparable to the 132 kDa p-galactosidase calibration standard is detected in the
pre-ejectate and ejectates (Figure 18). Given that the average mass of IgG1 is approximately 150
kDa, this variation from the expected mobility may be due to a change in conformation resulting
from the presence of the disulfide linkages.
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Figure 19: Non-reducing SDS-PAGE of Hepatitis B MAb.
Pre-ejectate and samples ejected using variable Vjet with constant Tjet and Vft.
* marks the migration of the heavy chain.
Marginal bands of higher relative molecular mass, possibly suggestive of aggregation,
are detected, albeit faintly, in all wells containing Hepatits B MAb. Their presence in the pre-
ejectate together with the observation that their intensity does not appear to change as Vjet
increases suggests that they may be an artefact of production and/or handling prior to or during
this study. However, it should be noted that if oligomers are present at less than two percent,
Coomassie Blue staining may not be sensitive enough to detect them. More sensitive dyes such
as silver stain (-10 times more sensitive) could be used in future. Finally, a second band having a
relative molecular weight comparable to the heavy chain is detected in all wells suggesting
41
denaturation of the MAb; the concentration of the corresponding light chain being too low for
detection by the Coomassie Blue stain. However, once again the presence of this band in all
wells does not suggest loss of integrity due to ejection.
4.4.2.2 Native gel electrophoresis
Evaluation of MAb integrity post ejection using native polyacrylamide gels shows the
presence of a single predominant band exceeding 216 kDa, in wells loaded with pre-ejectate or
post ejectate (Figure 20). However, determination of relative molecular mass in this case is
suspect as the conformation of the proteins comprising the calibration standards could affect
their migration. What can be stated is that the migration of the Hepatitis B MAb whether ejected
or not appears to be comparable suggesting that the net charge, shape, and size of this MAb has
not been altered as a result of ejection at increasing Vjet. This result in consistent with that
obtained for electrophoresis of the Hepatitis B MAb using non-reducing SDS-PAGE.
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Figure 20: Native polyacrylamide gel electrophoresis of Hepatitis B MAb pre-ejectates and samples ejected from
the nozzle of the needle-free jet injector at increasing velocities as marked below the appropriate lanes.
** designates the migration of the native conformation of the Hepatitis B MAb while the single * marks the
migration of the heavy chain.
4.4.2.3 IEF gel electrophoresis
Charge heterogeneity of monoclonal antibodies is often a result of deamidation events
(Daugherty & Mrsny, 2010). Deamidation involves the removal of an amide functional group
thereby damaging the amide-containing side chains of the amino acids asparagine and glutamine
(Robinson, 2001). It is considered to be relevant to the degradation of proteins and has been
postulated to limit the usefulness of certain recombinant therapeutic proteins
(www.ionsource.com). In antibody preparations, differences in charge distribution or content,
often markers for deamidation are detected by IEF gel electrophoresis or high performance
cation-exchange chromatography (www.dionex com). We has attempted to access changes in the
charge on the Hepatitis B MAb as a result of treatment using IEF gel electrophoresis.
Individual wells comprising IEF slab gels, pH 3 to 10, were loaded with 5 pg of Hepatitis
MAb ejected using variable jet speeds and electrophoresis and staining carried out as described
in Section 3.4.2.3. As shown in Figure 21, four prominent bands and two to three less intense
bands that together span a pI range of 6.5 to 7.5 were detected, consistent with the published
range for IgG (Hamilton, 2001).
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Figure 21: IEF gel electrophoresis of Hepatitis B MAb. MAb buffer containing 1 g/L Hepatitis B MAb was ejected
at variable velocity into test tubes and each sample analyzed by IEF gel electrophoresis.
Of the three less intense bands, one appears by Coomassie Blue staining to be of
comparable intensity in all samples having a pI of approximately 7.3. The remaining two bands
with pI's of less than 6.8 are more intense in the ejected samples, with intensity appearing to
increase with increasing velocity of ejection. While this interpretation is qualitative and needs to
be quantified by further experimentation, it suggests that ejection may be changing the charge on
the MAb which could result in its turnover.
5. Analysis
We initially hypothesized that the factors that might limit the ability of the jet injector to
be used for this application were the high viscosity of this formulation and the shearing of the
large monoclonal antibody particles during high ejection speeds.
From extensive studies on the ejection of glycerol solutions at varying formulations, we
have characterized the jet injector's ability to handle compounds of varying viscosities. We can
see that viscosity alone is not a limiting factor for the jet injector until the viscosity exceeds
about 49.7x 10-3 Pa-s (comparable to an 80 percent glycerol concentration). The monoclonal
antibody formulation has a known viscosity of approximately 69.4x 10-3 Pa*s for 175 g/L at 5'C
and 14.4x 103 Pa-s at 25'C. For a 130 g/L concentration of antibody, the viscosity is
approximately 16.Ox 10-3 Pa-s. With this limitation of viscosity, the jet injector would be unlikely
to effectively deliver monoclonal antibody at 175 g/L and 5oC without some redesign. This
redesign might present simply as an increased maximum voltage on the amplifier or a more
involved redesign of the ampoule to limit friction at the ampoule-piston interface.
The viscosity of 70 percent glycerol was a representative upper limit for that of MAb
concentrations ranging from 87 to 130 g/L at 5'C to 25'C. 175 g/L at 5'C, as mentioned
previously, exceeds the current capabilities for the jet injector system. Repeatability studies done
for up to 21.7x 10-3 Pa-s (70 percent glycerol solution) showed that even at increased viscosities
the feedback-control system within the jet injector contributed to fairly precise delivery volumes.
At 21.7x 10-3 Paos, the average standard deviation across all delivery volumes and jet velocities
was 2.9 pL, compared to 2.0 ptL for pure distilled water measured at 1.7x 103 Pa-s. With
continued improvements in the software of the jet injection system, we would hope to be able to
further optimize precision and accuracy.
The use of multiple coils (Figure 5), while necessary due to the lifetime of each coil,
presented some variations. Coil 3, used in conjunction with a more recently modified software,
was used for 50 and 70 percent glycerol and buffer formulation with MAb repeatability
ejections. Coil 3 had a resistance of 9.3 Q compared to the original 11.3 0 for Coil 1 and 2. This
lowered resistance allowed the amplifier to provide a lower voltage in order to achieve
equivalent jet velocities. The water calibration, which related voltage and velocity, indicated that
at lower velocities the jet injector did not have a significant difference in performance from when
it contained the Coil 1 and the original software. However, at higher velocities the new coil
requires less voltage. Further work would require a firmer grasp of the impact of the coil and
software on repeatability and control of injection waveforms.
Furthermore, it will be necessary to empirically measure viscosities of MAb solutions
from 1 g/L to the desired 175 g/L, at both 5'C and 25'C. We will also need to conduct
repeatability studies using solutions containing monoclonal antibodies in order to better evaluate
the jet injector's ability to eject MAb relative to comparably viscous glycerol solutions.
We assessed the monoclonal antibody's ability to handle high ejection speeds using two
primary methods: an ELISA and gel electrophoresis. The ELISA we ran showed data (Figure 17)
that would indicate that the conformational binding between the antigen HBsAg and MAb was
unhindered by ejection. This finding supported our belief that 1 g/L antibody had not aggregated
or degraded significantly.
Gel electrophoresis gave further evidence towards this conclusion. With SDS
polyacrylamide gel electrophoresis for non-reducing and reducing conditions, and for native gel
electrophoresis without the charging effects of SDS, we saw similar migration for each of the
ejectates compared to the pre-ejectate. As each of these experiments compared varying
combinations of molecular size and charge for pre- and post-ejectates, we can conclude that the
size and charge of the protein remained relatively unchanged as a result of ejection.
Our final gel electrophoresis method of isoelectric focusing revealed two faint bands of
pI less than 6.8, increasing in intensity with increasing jet velocity during ejection. These faint
bands may indicate changes in amino acid side-chains of the protein, in particular asparagine and
glutamine. Changes in these residues are used as indicators for the stability of monoclonal
antibody therapeutics. If this alteration in charge due to ejection can be quantified and revealed
to be significant, then the usefulness of the bio-therapeutic will be limited. In such an instance,
using the jet injector in a monoclonal antibody delivery application may not be feasible.
6. Conclusions and Future Work
We have conducted an initial set of tests to demonstrate the possibility of utilizing a
Lorentz-force actuated needle-free jet injector to deliver monoclonal antibodies. From
repeatability studies of glycerol and relations of the viscosity of glycerol concentrates with that
of monoclonal antibody solutions, we were able to characterize the performance of the jet
injector over increasing viscosities that might be relevant to the monoclonal antibody solutions.
Additionally, we conducted a first-pass analysis of the shearing of monoclonal antibody at high
velocities but relatively low concentrations (1 g/L). At this concentration, we determined using
two primary methods (ELISA and gel electrophoresis) that the monoclonal antibody was
unlikely to have significantly degraded or aggregated during ejection. However, two bands
displayed by ejectates during the IEF gel electrophoresis, which increase in intensity with
increasing jet velocity, indicate that jet ejection may have resulted in a change in the charge of
the molecule.
There are many future steps to be taken before we can recommend delivery of
monoclonal antibodies with the jet injector. We will need to attain a better understanding of the
characteristics of the jet injection system, particularly where the copper coil and the jet injection
software is concerned. We are aware that a shorter coil results in a lower resistance and thus a
different relationship between applied voltage and resultant jet velocity, but have not as of yet
been able to relate this information by comparing repeatability studies or evaluating system
limitations due to high viscosity fluids. The software system we have been using is still a work in
progress, and as such we will need to make some improvements to the waveforms of the new
software for better accuracy in jet velocity. We may also need to acquire injection ampoules
better suited for multiple high-velocity ejections and less inclined to piston wear and tear at high
pressures.
To fully evaluate the applicability of the jet injection system to injection of monoclonal
antibodies, further work would need to be done to test high-concentration monoclonal antibodies
(on the order of 175 g/L). Here we have demonstrated that viscosity alone should not prevent the
jet injector from effectively delivering fluid up to 130 g/L; however, there may be other factors
that contribute to the behavior of the system that cannot be accounted for until we eject the actual
monoclonal antibody concentrate. Additionally, at higher concentrations of monoclonal antibody
there will be a large number of antibody molecules trapped in the region close to the ampoule
wall. At this location, the shear forces due to the no-slip condition at the wall will affect a larger
number of the molecules.
In the future, we will need to pursue the possibility that jet ejection instigates a change of
charge for the molecule. As described previously, changes in charge may correlate with changes
in several key side-chains of the molecule. These residues are used as a marker of usefulness in
some bio-therapeutics, and thus may indicate protein turnover. We will require replication of
these data accompanied with a more quantitative assessment.
While we have begun to account for the ability of the jet injector to handle monoclonal
antibodies and the ability of the antibody to handle high-speed jet ejection, we have not yet
begun to characterize injection of the monoclonal antibodies. Injection of the monoclonal
antibody would require the jet fluid to impact with the surface of the skin before proceeding to
deliver to a precise depth. We will need to evaluate and then optimize the process of injection
into tissue analogues and then live animals.
Finally, we would require an assessment of the behavior of a wide range of monoclonal
antibodies using the jet injector before we can attempt to apply this delivery system to the
general application of injection of monoclonal antibodies in a clinical setting.
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